Association of urinary 6-sulfatoxymelatonin (aMT6s) levels and objective and subjective sleep measures in older men: The MrOS sleep study

for the Osteoporotic Fractures in Men (MrOS) Study Group

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background. Sleep and melatonin have been associated with healthy aging. In this study, we examine the association between melatonin levels and sleep among older men. Methods. Cross-sectional study of a community-dwelling cohort of 2,821 men aged 65 years or older recruited from six U.S. centers. First morning void urine samples were collected to measure melatonin-fs major urinary metabolite, 6-sulfatoxymelatonin (aMT6s). We also assessed objective and subjective sleep parameters. We used logistic regression models to calculate multivariate (MV) odds ratios (ORs), and 95% confidence intervals (CIs) adjusted for important demographic variables and comorbidities. Results. In the overall sample, the only significant finding in fully adjusted models was that aMT6s levels were inversely associated with subjectively measured daytime sleepiness (sleepiness mean score of 5.79 in the top aMT6s quartile, and 6.26 in the bottom aMT6s quartile, MV OR, 1.32; 95% CI, 0.95.1.84; ptrend ≤.02). When restricting to men without β-blocker use (a known melatonin suppressant), aMT6s levels were significantly associated with shorter sleep time, that is, less than 5 hours (MV OR, = 1.90; 95% CI, 1.21.2.99; ptrend =.01), and worse sleep efficiency, that is, less than 70% (MV OR, 1.58; 95% CI, 1.28-2.65; ptrend

Original languageEnglish (US)
Pages (from-to)1569-1577
Number of pages9
JournalJournals of Gerontology - Series A Biological Sciences and Medical Sciences
Volume70
Issue number12
DOIs
StatePublished - 2015

Fingerprint

Melatonin
Sleep
Odds Ratio
Confidence Intervals
Logistic Models
Independent Living
Comorbidity
Cross-Sectional Studies
Demography
6-sulfatoxymelatonin
Urine

Keywords

  • 6-Sulfatoxymelatonin
  • Actigraphy
  • Older men
  • Sleep efficiency
  • Sleepiness
  • Total sleep time

ASJC Scopus subject areas

  • Aging
  • Geriatrics and Gerontology

Cite this

Association of urinary 6-sulfatoxymelatonin (aMT6s) levels and objective and subjective sleep measures in older men : The MrOS sleep study. / for the Osteoporotic Fractures in Men (MrOS) Study Group.

In: Journals of Gerontology - Series A Biological Sciences and Medical Sciences, Vol. 70, No. 12, 2015, p. 1569-1577.

Research output: Contribution to journalArticle

@article{172283a43e4949fe8c3da319f84dad51,
title = "Association of urinary 6-sulfatoxymelatonin (aMT6s) levels and objective and subjective sleep measures in older men: The MrOS sleep study",
abstract = "Background. Sleep and melatonin have been associated with healthy aging. In this study, we examine the association between melatonin levels and sleep among older men. Methods. Cross-sectional study of a community-dwelling cohort of 2,821 men aged 65 years or older recruited from six U.S. centers. First morning void urine samples were collected to measure melatonin-fs major urinary metabolite, 6-sulfatoxymelatonin (aMT6s). We also assessed objective and subjective sleep parameters. We used logistic regression models to calculate multivariate (MV) odds ratios (ORs), and 95{\%} confidence intervals (CIs) adjusted for important demographic variables and comorbidities. Results. In the overall sample, the only significant finding in fully adjusted models was that aMT6s levels were inversely associated with subjectively measured daytime sleepiness (sleepiness mean score of 5.79 in the top aMT6s quartile, and 6.26 in the bottom aMT6s quartile, MV OR, 1.32; 95{\%} CI, 0.95.1.84; ptrend ≤.02). When restricting to men without β-blocker use (a known melatonin suppressant), aMT6s levels were significantly associated with shorter sleep time, that is, less than 5 hours (MV OR, = 1.90; 95{\%} CI, 1.21.2.99; ptrend =.01), and worse sleep efficiency, that is, less than 70{\%} (MV OR, 1.58; 95{\%} CI, 1.28-2.65; ptrend",
keywords = "6-Sulfatoxymelatonin, Actigraphy, Older men, Sleep efficiency, Sleepiness, Total sleep time",
author = "{for the Osteoporotic Fractures in Men (MrOS) Study Group} and Ingvild Saksvik-Lehouillier and Harrison, {Stephanie L.} and Lynn Marshall and Tranah, {Greg J.} and Kristine Ensrud and Sonia Ancoli-Israel and Aaron Clemons and Susan Redline and Stone, {Katie L.} and Schernhammer, {Eva S.}",
year = "2015",
doi = "10.1093/gerona/glv088",
language = "English (US)",
volume = "70",
pages = "1569--1577",
journal = "Journals of Gerontology - Series A Biological Sciences and Medical Sciences",
issn = "1079-5006",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Association of urinary 6-sulfatoxymelatonin (aMT6s) levels and objective and subjective sleep measures in older men

T2 - The MrOS sleep study

AU - for the Osteoporotic Fractures in Men (MrOS) Study Group

AU - Saksvik-Lehouillier, Ingvild

AU - Harrison, Stephanie L.

AU - Marshall, Lynn

AU - Tranah, Greg J.

AU - Ensrud, Kristine

AU - Ancoli-Israel, Sonia

AU - Clemons, Aaron

AU - Redline, Susan

AU - Stone, Katie L.

AU - Schernhammer, Eva S.

PY - 2015

Y1 - 2015

N2 - Background. Sleep and melatonin have been associated with healthy aging. In this study, we examine the association between melatonin levels and sleep among older men. Methods. Cross-sectional study of a community-dwelling cohort of 2,821 men aged 65 years or older recruited from six U.S. centers. First morning void urine samples were collected to measure melatonin-fs major urinary metabolite, 6-sulfatoxymelatonin (aMT6s). We also assessed objective and subjective sleep parameters. We used logistic regression models to calculate multivariate (MV) odds ratios (ORs), and 95% confidence intervals (CIs) adjusted for important demographic variables and comorbidities. Results. In the overall sample, the only significant finding in fully adjusted models was that aMT6s levels were inversely associated with subjectively measured daytime sleepiness (sleepiness mean score of 5.79 in the top aMT6s quartile, and 6.26 in the bottom aMT6s quartile, MV OR, 1.32; 95% CI, 0.95.1.84; ptrend ≤.02). When restricting to men without β-blocker use (a known melatonin suppressant), aMT6s levels were significantly associated with shorter sleep time, that is, less than 5 hours (MV OR, = 1.90; 95% CI, 1.21.2.99; ptrend =.01), and worse sleep efficiency, that is, less than 70% (MV OR, 1.58; 95% CI, 1.28-2.65; ptrend

AB - Background. Sleep and melatonin have been associated with healthy aging. In this study, we examine the association between melatonin levels and sleep among older men. Methods. Cross-sectional study of a community-dwelling cohort of 2,821 men aged 65 years or older recruited from six U.S. centers. First morning void urine samples were collected to measure melatonin-fs major urinary metabolite, 6-sulfatoxymelatonin (aMT6s). We also assessed objective and subjective sleep parameters. We used logistic regression models to calculate multivariate (MV) odds ratios (ORs), and 95% confidence intervals (CIs) adjusted for important demographic variables and comorbidities. Results. In the overall sample, the only significant finding in fully adjusted models was that aMT6s levels were inversely associated with subjectively measured daytime sleepiness (sleepiness mean score of 5.79 in the top aMT6s quartile, and 6.26 in the bottom aMT6s quartile, MV OR, 1.32; 95% CI, 0.95.1.84; ptrend ≤.02). When restricting to men without β-blocker use (a known melatonin suppressant), aMT6s levels were significantly associated with shorter sleep time, that is, less than 5 hours (MV OR, = 1.90; 95% CI, 1.21.2.99; ptrend =.01), and worse sleep efficiency, that is, less than 70% (MV OR, 1.58; 95% CI, 1.28-2.65; ptrend

KW - 6-Sulfatoxymelatonin

KW - Actigraphy

KW - Older men

KW - Sleep efficiency

KW - Sleepiness

KW - Total sleep time

UR - http://www.scopus.com/inward/record.url?scp=84959372383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959372383&partnerID=8YFLogxK

U2 - 10.1093/gerona/glv088

DO - 10.1093/gerona/glv088

M3 - Article

C2 - 26265731

AN - SCOPUS:84959372383

VL - 70

SP - 1569

EP - 1577

JO - Journals of Gerontology - Series A Biological Sciences and Medical Sciences

JF - Journals of Gerontology - Series A Biological Sciences and Medical Sciences

SN - 1079-5006

IS - 12

ER -